MeiraGTx Holdings plc
MGTXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How MGTX's past catalysts played out
adeno-associated virus vector AAV- CNGA3
Achromatopsia
AAV - CNGB3
Achromatopsia
AAV RPE65
Leber Congenital Amaurosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
adeno-associated virus vector AAV- CNGA3 | Phase 2 | Achromatopsia | - | - |
AAV - CNGB3 | Phase 2 | Achromatopsia | - | - |
AAV RPE65 | Phase 2 | Leber Congenital Amaurosis | - | - |
Frequently asked questions
What is in MeiraGTx Holdings plc's drug pipeline?→
CatalystAlert tracks 3 drug candidates in MeiraGTx Holdings plc's (MGTX) pipeline across Phase 2. Its lead program is adeno-associated virus vector AAV- CNGA3 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MeiraGTx Holdings plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MeiraGTx Holdings plc (MGTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MGTX biotech catalysts?→
Add MGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MeiraGTx Holdings plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.